Quality Overall Summary (QOS) Explained: Ultimate Guide for CTD/eCTD Submissions Mastering the Quality Overall Summary (QOS): Compliance-Ready Roadmap for Global Dossier Submissions Introduction to Quality Overall Summary and Its Importance The Quality Overall Summary (QOS) is one of the most critical sections of the Common Technical Document (CTD) and electronic CTD (eCTD). Found in Module 2, the QOS provides a concise but comprehensive summary of the data included in Module 3 (Quality). Regulatory agencies such as the U.S. FDA, EMA, PMDA, Health Canada, and CDSCO rely heavily on the QOS for their initial review of a dossier. The QOS serves…

QOS (Module 2.3): What Reviewers Scan First and How to Structure It for a Fast, Defensible Quality Review Designing a High-Impact Module 2.3: What Reviewers Read First and How to Structure Your QOS Why the QOS Matters: The 30-Minute Impression, Decision Shortcuts, and How to Earn Early Trust If Module 3 is the engine room of your dossier, the Quality Overall Summary (QOS, Module 2.3) is the bridge. It is the first quality document most assessors scan to decide how much work your file will be. In the first 30 minutes, reviewers want answers to four questions: (1) What is…

Linking the QOS to Module 3: Specs, Validation, and Stability Without Contradictions Make Your QOS Speak the Same Language as Module 3—And Prove It Why Cross-Linking Matters: One Truth Across 2.3 and 3.2—Not Two Parallel Realities The Quality Overall Summary (QOS, Module 2.3) is where assessors form their early judgment: does this dossier tell a consistent story about identity, controls, and shelf life—or will they chase contradictions for weeks? Every strong QOS accomplishes three things. First, it summarizes what matters (specifications, validation, stability, and control strategy). Second, it points exactly to where evidence lives in 3.2.S and 3.2.P with table…

QOS for ANDA vs NDA: Depth, Justifications, and the Deficiency Traps to Avoid Tailoring Your Module 2.3 for ANDAs and NDAs—Right-Sized Depth, Strong Justifications, Fewer Deficiencies Introduction: Same Template, Different Burden—What Changes Between ANDA and NDA QOS The Quality Overall Summary (QOS, Module 2.3) is structurally identical across applications, but the burden of persuasion is not. In an ANDA, the QOS must prove sameness where it matters (API form where applicable, dosage form, strength, route) and equivalence where sameness is impossible (performance via dissolution profile alignment and bioequivalence). In an NDA—particularly a 505(b)(1) or a 505(b)(2) relying partly on literature…

Biologics QOS (Module 2.3): Potency, Comparability, and a Control Strategy That Survives Inspection Writing the Biologics QOS: Proving Potency, Passing Comparability, and Making Your Control Strategy Obvious Why the Biologics QOS Is Different: MoA-Linked Potency, Living Processes, and Reviewer Expectations Biologics are made, not merely mixed. That reality shifts what reviewers scan first in the Quality Overall Summary (QOS, Module 2.3). For small molecules, an assessor will go straight to specifications and stability. For biologics, the first pass is: (1) does the potency strategy reflect the mechanism of action (MoA) with an assay (or orthogonal assays) that track clinical effect;…

Using FDA Product-Specific Guidances and the IID to Power QOS Justifications Turn PSGs and the IID into Evidence That Makes Your QOS Reviewer-Proof Why PSGs and the IID Belong at the Heart of Your QOS: Fast Trust, Fewer IRs, Cleaner Decisions The Quality Overall Summary (QOS, Module 2.3) lives or dies by how quickly a reviewer can verify that your controls and choices are credible and aligned with precedent. Two public resources can do more heavy lifting for your QOS than almost anything else: FDA’s Product-Specific Guidances (PSGs) and the Inactive Ingredient Database (IID). PSGs tell you, for a particular…

QOS for Complex Generics: In-Vitro/Device Aspects and a Clear Bioequivalence Story Writing a QOS for Complex Generics with In-Vitro and Device Evidence that Supports Bioequivalence Purpose and Scope: Why Complex Generics Need a Focused QOS The Quality Overall Summary (QOS, Module 2.3) for complex generics must give reviewers a fast, reliable view of product performance and its link to the bioequivalence (BE) plan. For these products, the main questions are practical and predictable: What is the product and how does it perform in vitro? If a device is part of the product, does the device deliver the dose as intended?…

Handling Changes in the QOS: Versioning and Traceability Through the Product Lifecycle Managing QOS Changes Across the Lifecycle: Simple Versioning and Reliable Traceability Purpose and Scope: Why QOS Versioning and Traceability Matter The Quality Overall Summary (QOS, Module 2.3) is the reviewer’s first view of your quality story. After approval, data and controls evolve: specifications change, methods improve, sites are added, devices update, and labels are aligned. If the QOS does not keep pace, reviewers see conflicting statements between 2.3 and Module 3, which leads to avoidable questions. A simple and disciplined approach to versioning and traceability keeps the QOS…

QOS Writing Templates (Module 2.3): Headings, Tables, and Reviewer Navigation That Work Module 2.3 Writing Templates: Simple Headings, High-Value Tables, and Easy Reviewer Navigation Purpose and Scope: What a QOS Template Must Achieve A good Quality Overall Summary (QOS, Module 2.3) template saves time for both authors and reviewers. It does this by presenting the key quality story in a short, stable structure that matches the Common Technical Document (CTD) and points straight to evidence in Module 3. The template should help the author keep language plain, numbers consistent, and references exact. It should also let the reviewer find the…

QOS QC Checklist (Module 2.3): A Fast, Reliable Review Before You Publish QOS Quality Control: A Simple Checklist to Clear Red Flags Before Dispatch Purpose and Scope: What This QC Pass Must Prove in Minutes A Quality Overall Summary (QOS, Module 2.3) should be short, exact, and consistent with Module 3. The final quality control pass must confirm three outcomes in minutes: (1) every number and name in QOS tables matches the approved or proposed Module 3 content; (2) each claim has a direct pointer to a controlled record (specification row, validation report, stability conclusion); and (3) reviewers can reach…